US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Xtrackers Nifty 500 India ETF

24.65

-0.3150-1.26%

Volume:203.00

Turnover:5.00K

Market Cap:4.93M

PE:- -

High:24.65

Open:24.65

Low:24.65

Close:24.97

52wk High:27.40

52wk Low:23.33

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.23

T/O Rate:0.10%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

BioRestorative Announces Positive Outcome from Type B Meeting with FDA

Taiwan FDA OKs Heron Neutron Medical IND Application for Imaging Drug

MT Newswires Live

Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development

BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease

Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy

Jiuyuan Biopharma Advances JY54 Obesity Drug as China CDE Accepts IND

JIUYUAN GENE's IND Application for JY54 Injection Accepted by Regulatory Center

InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China

Ascentage Pharma announces IND clearance by the China CDE for APG-3288

Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288

Transcode Therapeutics, Quantum Leap submit IND for Phase 2a trial of TTX-MC138

Arovella Wins FDA IND Clearance as It Enters Clinical Stage With CAR-iNKT Cancer Therapy

Indian shares pause after US trade-deal rally; IT stocks weigh

India Ratings Reaffirms VA Tech Wabag’s ‘IND AA-/Stable’ Credit Ratings

Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

Oragenics partners with Duck Flats Pharma to support FDA IND trial design

Wuhan YZY Biopharma Wins FDA IND Approval for Bispecific Antibody M701 in Malignant Pleural Effusion

YZYBIO-B (02496): M 701 Receives FDA IND Approval

US to Cut Tariffs on India to 18%, India Agrees to End Russian Oil Purchases

Imagion Biosystems Files IND with FDA for Phase 2 MagSense HER2 Breast Cancer Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IND/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":24.65,"timestamp":1770823077361,"preClose":24.965,"halted":0,"volume":203,"delay":0,"changeRate":-0.012617664730622924,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"Trading","change":-0.315,"latestTime":"02-11 10:31:56 EST","open":24.65,"high":24.65,"low":24.65,"amount":5001.324398,"amplitude":0,"askPrice":24.62,"askSize":100,"bidPrice":24.5,"bidSize":1,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770843600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":24.965,"sharesOutstanding":200001,"nav":24.467,"aum":4893442.38,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.81,"preClose":24.965,"latestTime":"16:09 EST","volume":1,"amount":25.32,"timestamp":1770757750977,"change":-0.155,"changeRate":-0.006209,"amplitude":0},"volumeRatio":0.229326},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","floatShares":200001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.229326,"shares":200001,"dividePrice":0,"high":24.65,"amplitude":0,"preClose":24.965,"low":24.65,"week52Low":23.3301,"pbRate":"--","week52High":27.4,"institutionHeld":0,"latestPrice":24.65,"committee":-0.980198,"eps":0,"divideRate":0,"volume":203,"delay":0,"ttmEps":0,"open":24.65,"prevYearClose":24.78,"prevWeekClose":24.535,"prevMonthClose":23.8555,"prevQuarterClose":24.78,"fiveDayClose":24.41,"twentyDayClose":24.31},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IND\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610327409","title":"BioRestorative Announces Positive Outcome from Type B Meeting with FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2610327409","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610327409?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:30","pubTimestamp":1770813000,"startTime":"0","endTime":"0","summary":"BioRestorative completed a Type B meeting with the U.S. Food and Drug Administration (“FDA”) regarding a potential accelerated Biologics License Application (“BLA”) approval pathway for the Fast-Track","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/11/3236180/0/en/BioRestorative-Announces-Positive-Outcome-from-Type-B-Meeting-with-FDA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0971096721.USD","BRTX","IE00BKVL7J92.USD","IE00BHPRN162.USD","CMC","IE00B1BXHZ80.USD","LU0170899867.USD","LU2237443465.HKD","LU1363072403.SGD","LU0149725797.USD","LU0267386448.USD","LU2746668461.USD","LU0882574139.USD","BK4139","LU2237443978.SGD","BK4006","LU2237443895.HKD","LU2237443549.SGD","IE00BZ1G4Q59.USD","LU2237443622.USD","LU2237443382.USD","IND","IE00BFXG1179.USD","LU2746668974.SGD"],"gpt_icon":0},{"id":"2610604468","title":"Taiwan FDA OKs Heron Neutron Medical IND Application for Imaging Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2610604468","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610604468?lang=en_us&edition=fundamental","pubTime":"2026-02-11 12:03","pubTimestamp":1770782583,"startTime":"0","endTime":"0","summary":"Heron Neutron Medical  said Taiwan's Food and Drug Administration has in-principle approved its resubmitted investigational new drug  application for F18 FBPA Injection, according to a Tuesday Taiwan Exchange filing.Shares gained about 3% in Wednesday's late morning trade.F18 FBPA is an imaging drug used in PET/CT scans to check tumors and test its safety and effectiveness.The approval allows the company to proceed with Phase I and Phase II academic human clinical trials.The IND was resubmitted on Dec. 8, 2025, and the company received notification of approval on Feb. 10, 2026.Heron said no manufacturer worldwide has obtained regulatory approval for F18 FBPA, making the study a first-in-human trial.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IND","IND.AU","BK7095"],"gpt_icon":0},{"id":"2610109677","title":"Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2610109677","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610109677?lang=en_us&edition=fundamental","pubTime":"2026-02-11 07:15","pubTimestamp":1770765300,"startTime":"0","endTime":"0","summary":"- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology , ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state, in non-human primate  studies.- In NHPs, ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once-daily dosing for 7 days. ASC36 tablets also reduced food intake significantly.- In a head-to-head diet-induced obese  rat model, ASC36 demonstrated approximately 32% and 91% greater relative body weight reduction compared to eloralintide and petrelintide, respectively.- Submission of an Investigational New Drug Application  to the U.S. Food and Drug Administration  for ASC36 oral tablets is expected in the second quarter of 2026.HONG KONG, Feb. 11, 2026 /PRNewswire/ -- Ascletis Pharma Inc.  announces that it has selected ASC36 oral tablets, its first oral amylin receptor peptide agonist, for clinical development. Ascletis expects to submit an Investigational New Drug Application  to the U.S. Food and Drug Admini","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ascletis-selects-oral-amylin-receptor-peptide-agonist-asc36-for-clinical-development-302683760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK7095","IND.AU"],"gpt_icon":0},{"id":"2610262358","title":"BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2610262358","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610262358?lang=en_us&edition=fundamental","pubTime":"2026-02-10 21:00","pubTimestamp":1770728400,"startTime":"0","endTime":"0","summary":"Largest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc diseaseThe study has enrolled a total of 99 participants, each of whom was randomized to receive either BRTX-100 or p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/10/3235257/0/en/BioRestorative-Completes-Patient-Enrollment-in-Landmark-Phase-2-Trial-of-BRTX-100-for-Chronic-Lumbar-Disc-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRTX","BK4139","IND","BK4211","LARK"],"gpt_icon":0},{"id":"2610655338","title":"Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2610655338","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610655338?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:30","pubTimestamp":1770643800,"startTime":"0","endTime":"0","summary":"Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI) Fully prepared to initiate near-term clinical site onboarding and first patient dosing in Austra","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/09/3234525/0/en/Oragenics-Targets-Projected-9-Billion-Market-by-Advancing-First-and-Only-Clinical-Stage-Concussion-and-Mild-Traumatic-Brain-Injury-Therapy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OGEN","BK4139","CDC","IND","SSI"],"gpt_icon":0},{"id":"2610263310","title":"Jiuyuan Biopharma Advances JY54 Obesity Drug as China CDE Accepts IND","url":"https://stock-news.laohu8.com/highlight/detail?id=2610263310","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610263310?lang=en_us&edition=fundamental","pubTime":"2026-02-09 17:08","pubTimestamp":1770628085,"startTime":"0","endTime":"0","summary":"Hangzhou Jiuyuan Gene Engineering Co Ltd Class H ( ($HK:2566) ) has shared an announcement. Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/jiuyuan-biopharma-advances-jy54-obesity-drug-as-china-cde-accepts-ind?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/jiuyuan-biopharma-advances-jy54-obesity-drug-as-china-cde-accepts-ind?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1223082196.USD","LU1223082519.USD","CDE","LU1223083913.SGD","BK4017","IND"],"gpt_icon":0},{"id":"1124058623","title":"JIUYUAN GENE's IND Application for JY54 Injection Accepted by Regulatory Center","url":"https://stock-news.laohu8.com/highlight/detail?id=1124058623","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124058623?lang=en_us&edition=fundamental","pubTime":"2026-02-09 17:01","pubTimestamp":1770627662,"startTime":"0","endTime":"0","summary":"JIUYUAN GENE (02566) has announced that the Investigational New Drug (IND) application for its self-developed Class 1 chemical innovative drug, JY54 injection, has been formally accepted by the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1223083913.SGD","BK1161","IND","LU1223082519.USD","CDE","02566","LU1223082196.USD","BK4017"],"gpt_icon":0},{"id":"2610507743","title":"InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2610507743","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610507743?lang=en_us&edition=fundamental","pubTime":"2026-02-09 10:43","pubTimestamp":1770604980,"startTime":"0","endTime":"0","summary":"BEIJING, Feb.  08, 2026  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/09/3234225/0/en/InnoCare-Announces-IND-Approval-to-Initiate-Clinical-Trial-of-VAV1-Degrader-ICP-538-in-China.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1223083913.SGD","IND","LU1223082519.USD","CDE","LU1223082196.USD","BK4017"],"gpt_icon":0},{"id":"2609533250","title":"Ascentage Pharma announces IND clearance by the China CDE for APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533250","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609533250?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:35","pubTimestamp":1770334517,"startTime":"0","endTime":"0","summary":"Ascentage Pharma (AAPG) “announced that its novel next-generation Bruton’s tyrosine kinase-targeted protein degrader, APG-3288, has received invest...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-announces-ind-clearance-by-the-china-cde-for-apg-3288-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-announces-ind-clearance-by-the-china-cde-for-apg-3288-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1223083913.SGD","BK4129","APG","CDE","LU1223082519.USD","BK4139","BK4017","IND","LU2125909916.SGD","LU2125909759.SGD","AAPG","LU1223082196.USD","LU1923622291.USD"],"gpt_icon":0},{"id":"2609533068","title":"Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533068","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609533068?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:30","pubTimestamp":1770334200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Feb.  05, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/05/3233530/0/en/Ascentage-Pharma-Announces-IND-Clearance-by-the-China-CDE-for-BTK-Degrader-APG-3288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909916.SGD","LU2298064838.USD","LU2041044095.USD","LU2023251221.USD","LU1430594728.SGD","LU1989772840.SGD","LU2089283258.USD","LU0057025933.USD","LU2463526074.USD","PK","WM","CDE","IND","BK4585","LU1939255532.USD","LU2023250504.SGD","LU0289960550.SGD","LU2240825500.USD","BK4588","LU2271345857.HKD","LU2308191902.HKD","LU1917777945.USD","LU2238339852.HKD","LU2125909759.SGD","LU2089284900.SGD","LU0472753341.HKD","LU1892829315.USD","LU1712237335.SGD","LU2362541513.USD","LU2111349929.HKD","BCR","BK4181","LU2413666426.HKD","LU1223082196.USD","LU1923621640.USD","LU1923622291.USD","BK4139","APG","LU2106854487.HKD","LU0289739343.SGD","LU0158827948.USD","LU0124676726.USD","LU2413666699.HKD","AAPG","LU1223083913.SGD","LU2362540622.SGD","LU0511384066.AUD","LU0347712357.USD","BK4533","LU1989772923.USD"],"gpt_icon":0},{"id":"2609036913","title":"Transcode Therapeutics, Quantum Leap submit IND for Phase 2a trial of TTX-MC138","url":"https://stock-news.laohu8.com/highlight/detail?id=2609036913","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609036913?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:12","pubTimestamp":1770297136,"startTime":"0","endTime":"0","summary":"TransCode Therapeutics (RNAZ), in collaboration with Quantum Leap Healthcare Collaborative, announced the submission to the U.S. FDA of an Investig...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/transcode-therapeutics-quantum-leap-submit-ind-for-phase-2a-trial-of-ttx-mc138-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/transcode-therapeutics-quantum-leap-submit-ind-for-phase-2a-trial-of-ttx-mc138-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND","XLV","XBI","BK4007","BK4139","LENZ","BK4588","BK4539","BK4581","RNAZ","BK4585","LABU"],"gpt_icon":0},{"id":"2609319478","title":"Arovella Wins FDA IND Clearance as It Enters Clinical Stage With CAR-iNKT Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2609319478","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609319478?lang=en_us&edition=fundamental","pubTime":"2026-02-05 06:19","pubTimestamp":1770243555,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics Limited ( ($AU:ALA) ) has shared an announcement. Arovella Therapeutics has become a clinical‑stage company after the US Food...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arovella-wins-fda-ind-clearance-as-it-enters-clinical-stage-with-car-inkt-cancer-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arovella-wins-fda-ind-clearance-as-it-enters-clinical-stage-with-car-inkt-cancer-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4230","CAR","SSI","IND","BK4022"],"gpt_icon":0},{"id":"2608331983","title":"Indian shares pause after US trade-deal rally; IT stocks weigh","url":"https://stock-news.laohu8.com/highlight/detail?id=2608331983","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608331983?lang=en_us&edition=fundamental","pubTime":"2026-02-04 13:06","pubTimestamp":1770181575,"startTime":"0","endTime":"0","summary":"REFILE-INDIA STOCKS-Indian shares pause after US trade-deal rally; IT stocks weighCorrects to drop extraneous word from paragraph 1By Bharath Rajeswaran and Vivek Kumar M","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nL4N3Z00AP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIN","LU0898667661.SGD","LU2265009873.SGD","BK4134","LU0708995666.HKD","LU0231203729.USD","EPI","INCO","LU1508157978.USD","LU0348744763.USD","INDL","INDY","LU0431992006.USD","LU1366334578.USD","SMIN","LU1805238398.USD","LU2663582299.SGD","IND","BK4523","INXX","IE00B0JY6M65.USD","LU0791590937.USD","IE00BYTNYM70.SGD","LU0536402901.SGD","LU1804176565.USD","LU0164881194.USD","LU0890818403.SGD","LU0868486357.SGD","LU0831103253.SGD","LU0862451753.SGD","LU0197229882.USD","LU0531971678.HKD","INDA","LU0333810181.USD","IE00B3M56506.USD","LU1366334651.USD","LU0791591158.USD","SCIN","IE00B7N09G41.SGD","LU0287143357.SGD","LU0066902890.USD","BK4533","BK4585","BK4535","LU1267930656.SGD","LU2087589342.USD","FLIN","NFTY","LU1323998911.USD","LU1102505762.USD","BK4588"],"gpt_icon":0},{"id":"2608693336","title":"India Ratings Reaffirms VA Tech Wabag’s ‘IND AA-/Stable’ Credit Ratings","url":"https://stock-news.laohu8.com/highlight/detail?id=2608693336","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608693336?lang=en_us&edition=fundamental","pubTime":"2026-02-04 11:23","pubTimestamp":1770175409,"startTime":"0","endTime":"0","summary":"VA Tech Wabag Limited ( ($IN:WABAG) ) has issued an update. VA Tech Wabag Limited announced that India Ratings & Research has reaffirmed its credit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/india-ratings-reaffirms-va-tech-wabags-ind-aa-stable-credit-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/india-ratings-reaffirms-va-tech-wabags-ind-aa-stable-credit-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND","MNDmain"],"gpt_icon":0},{"id":"2608874147","title":"Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2608874147","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608874147?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:45","pubTimestamp":1770126300,"startTime":"0","endTime":"0","summary":"Access the “What This Means” segmenthere CAMBRIDGE, Mass., Feb.  03, 2026  (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatme","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/03/3231107/0/en/Ernexa-Therapeutics-Participates-in-Virtual-Investor-What-This-Means-Segment-Highlighting-Recent-Successful-Pre-IND-Meeting-with-U-S-FDA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4539","BK4139","IND","LENZ","BK4007"],"gpt_icon":0},{"id":"2608487459","title":"Oragenics partners with Duck Flats Pharma to support FDA IND trial design","url":"https://stock-news.laohu8.com/highlight/detail?id=2608487459","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608487459?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:40","pubTimestamp":1770126046,"startTime":"0","endTime":"0","summary":"Oragenics (OGEN) announced it has engaged Duck Flats Pharma as its U.S. Investigational New Drug, IND, readiness and regulatory execution partner t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oragenics-partners-with-duck-flats-pharma-to-support-fda-ind-trial-design-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oragenics-partners-with-duck-flats-pharma-to-support-fda-ind-trial-design-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND","OGEN","BK4139"],"gpt_icon":0},{"id":"2608582220","title":"Wuhan YZY Biopharma Wins FDA IND Approval for Bispecific Antibody M701 in Malignant Pleural Effusion","url":"https://stock-news.laohu8.com/highlight/detail?id=2608582220","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608582220?lang=en_us&edition=fundamental","pubTime":"2026-02-03 18:40","pubTimestamp":1770115213,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Wuhan YZY Biopharma Co., Ltd. Class H ( ($HK:2496) ). Wuhan YZY Biopharma Co., Ltd. has secured U.S. FDA approv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/wuhan-yzy-biopharma-wins-fda-ind-approval-for-bispecific-antibody-m701-in-malignant-pleural-effusion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/wuhan-yzy-biopharma-wins-fda-ind-approval-for-bispecific-antibody-m701-in-malignant-pleural-effusion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND"],"gpt_icon":0},{"id":"1161842676","title":"YZYBIO-B (02496): M 701 Receives FDA IND Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1161842676","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161842676?lang=en_us&edition=fundamental","pubTime":"2026-02-03 18:14","pubTimestamp":1770113661,"startTime":"0","endTime":"0","summary":"YZYBIO-B (02496) announced that on January 31, 2026, the Investigational New Drug (IND) application for Recombinant Anti-EpCAM and CD3 Human-Mouse Chimeric Bispecific Antibody for Injection (M 701)...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","02496","BK1161"],"gpt_icon":0},{"id":"1158736809","title":"US to Cut Tariffs on India to 18%, India Agrees to End Russian Oil Purchases","url":"https://stock-news.laohu8.com/highlight/detail?id=1158736809","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158736809?lang=en_us&edition=fundamental","pubTime":"2026-02-03 01:06","pubTimestamp":1770051961,"startTime":"0","endTime":"0","summary":"WASHINGTON/NEW DELHI, Feb 2 (Reuters) - U.S. President Donald Trump on Monday announced a trade deal with India that slashes U.S. tariffs on Indian goods to 18% from 50% in exchange for India halting...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"US to Cut Tariffs on India to 18%, India Agrees to End Russian Oil Purchases","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDY","INXX","NFTY","PIN","IND","FLIN","INDL","INCO","EPI","SCIN","SMIN","INDA"],"gpt_icon":0},{"id":"2608887603","title":"Imagion Biosystems Files IND with FDA for Phase 2 MagSense HER2 Breast Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2608887603","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608887603?lang=en_us&edition=fundamental","pubTime":"2026-02-02 07:48","pubTimestamp":1769989731,"startTime":"0","endTime":"0","summary":"Imagion Biosystems Ltd. ( ($AU:IBX) ) has issued an announcement. Imagion Biosystems has submitted its first Investigational New Drug application t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/imagion-biosystems-files-ind-with-fda-for-phase-2-magsense-her2-breast-cancer-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/imagion-biosystems-files-ind-with-fda-for-phase-2-magsense-her2-breast-cancer-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":113,"code":"91000000","status":"200"}]}}